162. 類天疱瘡(後天性表皮水疱症を含む。) [臨床試験数:70,薬物数:117(DrugBank:46),標的遺伝子数:30,標的パスウェイ数:128

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR20000290072020-01-012020-01-11Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoidClinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid Bullous Pemphigoidexperimental group:subclinical dosage of Cyclosporine, Prednisone or Methylprednisolone and Halometasone Cream.;control group:Prednisone or Methylprednisolone, Halometasone Cream;The First Affiliated Hospital of Kunming Medical UniversityNULLRecruitingBothexperimental group:30;control group:30;China
2EUCTR2018-001417-32-FR13/07/201811/06/2018Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation Patients with Bullous pemphigoid included in RITUXIMAB3 study
MedDRA version: 20.0Level: LLTClassification code 10006567Term: Bullous pemphigoidSystem Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: MABTHERA
INN or Proposed INN: RITUXIMAB
Trade Name: Prednisone
Product Name: CORTANCYL 20 mg
INN or Proposed INN: PREDNISONE
Other descriptive name: PREDNISONE
Trade Name: Prednisone
Product Name: CORTANCYL 20 mg
INN or Proposed INN: PREDNISONE
Other descriptive name: PREDNISONE
CHU-Hôpitaux de RouenNULLNot RecruitingFemale: yes
Male: yes
77Phase 3France
3ChiCTR-TRC-120035932011-08-012012-12-30Use of Oral Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trialGuideline-oriented Research in the Management of Some Common and Severe Skin Diseases bullous pemphigoidGlucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses.;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;Institute of dermatology; Chinese Academy of Medical SciencesNULLCompleted18BothGlucocorticoids group:90;Glucocorticoid plus MTX group:90;China
4ChiCTR-TRC-120035382011-08-012012-12-27Use of inravenous Methotrexate plus Glucocorticoid for the Treatment of bullous pemphigoid:A multicenter,randomized and controlled clinincal trialGuideline-oriented Research in the Management of Some Common and Severe Skin Diseases Bullous pemphigoidGlucocorticoids group:This group receives systemic glucocorticoid, initially, with prednisone at 1mg/kg/day. Then we adjust the dose of glucocorticoid according to the patients' responses;Glucocorticoid plus MTX group:This group receives systemic glucocorticoid plus MTX and starts with prednisone at 1mg/kg/day and MTX IV drip infusion at 15mg/week. Then we adjust the dose of glucocorticoid according to the patients' responses.;Institute of dermatology, Chinese Academy of Medical SciencesNULLRecruiting180BothGlucocorticoids group:90;Glucocorticoid plus MTX group:90;China
5EUCTR2008-005266-31-FR06/02/200913/03/2009COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab IIICOMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ LES PATIENTS ATTEINTS DE PEMPHIGUS - Rituximab III Pemphogoide bulleuse
MedDRA version: 9.1Level: LLTClassification code 10006567Term: Bullous pemphigoid
Trade Name: mabthéra
Product Name: mathéra
Trade Name: Prednisone
Product Name: CORTANCYL 20 mg
CHU-Hôpitaux de RouenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00472030August 20078/5/2007Efficacy and Safety of Omalizumab in Bullous PemphigoidAn Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous PemphigoidBullous PemphigoidDrug: Omalizumab;Drug: prednisoneUniversity of IowaGenentech, Inc.Completed18 YearsN/AAll2Phase 4United States